Martin Auster Biography and Net Worth

CFO of Ventyx Biosciences

Marty serves as our Chief Financial Officer. Before joining Ventyx, he served as Managing Director, Biotechnology Analyst at Credit Suisse, where he led the bank’s global biotechnology equity research effort. Marty also previously served as an executive at Ascendis Pharma and United Therapeutics. Earlier in his career, he held positions of increasing responsibility in the investment banking industry, including as a Senior Biotechnology Analyst at Wachovia Securities and a Senior Analyst/Healthcare-focused Portfolio Manager at GLG Partners. He received a BA from the University of Michigan and an MD from the University of Texas Medical Branch.

What is Martin Auster's net worth?: The estimated net worth of Martin Auster is at least $339.27 thousand as of April 2nd, 2024. Dr. Auster owns 24,303 shares of Ventyx Biosciences stock worth more than $339,270 as of February 24th. This net worth evaluation does not reflect any other assets that Dr. Auster may own. Learn More about Martin Auster's net worth.
How do I contact Martin Auster?: The corporate mailing address for Dr. Auster and other Ventyx Biosciences executives is , , . Ventyx Biosciences can also be reached via phone at 760-593-4832 and via email at [email protected]. Learn More on Martin Auster's contact information.
Has Martin Auster been buying or selling shares of Ventyx Biosciences?: Martin Auster has not been actively trading shares of Ventyx Biosciences within the last three months. Most recently, Martin Auster sold 1,405 shares of the business's stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $5.40, for a transaction totalling $7,587.00. Following the completion of the sale, the chief financial officer now directly owns 24,303 shares of the company's stock, valued at $131,236.20. Learn More on Martin Auster's trading history.
Who are Ventyx Biosciences' active insiders?: Ventyx Biosciences' insider roster includes Martin Auster (CFO), Sheila Gujrathi (Director), Christopher Krueger (Insider), Raju Mohan (CEO), and John Nuss (Insider). Learn More on Ventyx Biosciences' active insiders.
Are insiders buying or selling shares of Ventyx Biosciences?: During the last year, insiders at the sold shares 2 times. They sold a total of 60,020 shares worth more than $463,354.40. The most recent insider tranaction occured on December, 18th when CEO Raju Mohan sold 47,345 shares worth more than $365,503.40. Insiders at Ventyx Biosciences own 18.2% of the company. Learn More about insider trades at Ventyx Biosciences.
Information on this page was last updated on 12/18/2025.

Martin Auster Insider Trading History at Ventyx Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/2/2024	Sell	1,405	$5.40	$7,587.00	24,303
7/25/2023	Sell	28,000	$35.54	$995,120.00	47,649
6/6/2023	Sell	28,000	$34.64	$969,920.00	47,649
4/25/2023	Sell	28,000	$38.04	$1,065,120.00	47,649
4/17/2023	Sell	7,000	$33.00	$231,000.00	47,649
4/4/2023	Sell	21,000	$30.76	$645,960.00	47,649
12/2/2022	Sell	97,647	$29.01	$2,832,739.47	47,649

Martin Auster Buying and Selling Activity at Ventyx Biosciences

Ventyx Biosciences Company Overview

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Today's Range

Now: $13.96

$13.95

$13.97

50 Day Range

MA: $12.40

$7.69

$14.03

2 Week Range

Now: $13.96

$0.78

$25.00

Volume

1,099,301 shs

Average Volume

4,587,494 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25